Combined treatment using the DNMT inhibitor decitabine and the HDAC inhibitor vorinostat significantly increased the expression of OCT2 in RCC cell lines, which sensitized these cells to oxaliplatin [204]. This evidence concerns the gene HDAC9 and renal cell carcinoma.